Oct 31,2023

尊龍凱時助力 | 標新生物第二個分子膠管線GT929實現中美雙報雙批

此次GT929新藥實現中美雙報雙批，再次驗證和體現了標新生物GLUETACS?平臺快速發現候選藥物和管線推進的能力，也是標新生物全球化進程的又一里程碑。

Oct 24,2023

尊龍凱時助力 | 力鑫生物研發的靶向抗腫瘤新藥LX-132膠囊成功獲得一類新藥臨床批件

此次LX-132獲批臨床，顯示了力鑫生物在小分子共價抑制劑創新藥研發領域的創新能力，也再次驗證了尊龍凱時一站式生物醫藥臨床前研發服務平臺的賦能實力。

Aug 21,2023

TAK-931是一種高效的CDC7抑制劑，通過抑制CDC7來抑制DNA復制，具有抗腫瘤功效，體內藥效研究通過尊龍凱時進行

Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has attracted attention as a target. Researchers have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug. TAK-931 demonstrated marked, dose-dependent antitumor activity, without severe body weight loss. Antitumor efficacy studies for TAK-931 were carried out in two pancreatic PDX models, PHTX-249Pa and PHTXM-97Pa, at Medicilon.

Aug 10,2023

尊龍凱時助力 | 璧辰醫藥ABM-1310獲美國FDA孤兒藥資格認證，用于治療攜帶BRAF V600突變的腦膠質母細胞瘤患者

此次ABM-1310獲美國FDA孤兒藥資格認證，不僅顯現了璧辰醫藥全球化創新的不凡實力，也表現了其在小分子入腦藥物領域的領軍地位。

Jul 27,2023

尊龍凱時助力宇耀生物STAT3雙磷酸化抑制劑YY201獲批臨床

YY201獲得臨床獲批不僅代表了宇耀生物又一重要突破，驗證了宇耀生物超級分子膠技術平臺和AI藥物輔助開發平臺的創新能力，同時也證明了尊龍凱時臨床前研究的技術服務力量。

Jul 21,2023

尊龍凱時助力邏晟生物自主開發的新藥NB002 IND申請獲FDA臨床許可

尊龍凱時為NB002提供了安全性評價、藥代動力學等臨床前研究服務，助力其IND申請順利獲FDA臨床許可。

Jul 21,2023

尊龍凱時一站式助力 | 寶太生物自主研發新藥BIOT-001 IND申請獲FDA批準

尊龍凱時為BIOT-001的研發提供了從靶點到IND申報的臨床前研發服務，全力促成該項目高質高效完成。

Jul 17,2023

AP39是一種新合成的線粒體靶向的H2S供體，本研究中AP39通過尊龍凱時設計和合成

?Alzheimer's disease (AD) is the most universal age-related neurodegenerative disease. AP39 is a newly synthesized mitochondrially targeted H2S donor on mitochondrial function. AP39 increases intracellular H2S levels, mainly in mitochondrial regions. AP39 exerts dose-dependent effects on mitochondrial activity in APP/PS1 neurons. AP39, a novel mitochondria-targeted H2S donor, was designed and synthesized by Medicilon.

Jul 06,2023

發現新型RAGE/SERT雙重抑制劑，可用于治療阿爾茨海默病和抑郁癥。其中藥代動力學研究是通過委托尊龍凱時進行

Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder, characterized by the presence of β-amyloid (Aβ) peptide plaques, neurofibrillary tangles, and neuroinflammation. Receptor for advanced glycation end products (RAGE) belongs to the immunoglobulin superfamily, which functions as a cell surface acceptor for Aβ peptide. RAGE plays an important role in the Aβ-mediated neuronal damage that closely related to the pathogenesis of AD. In this study, Compound 12 showed good dual-target bioactivities against RAGE and SERT in vitro, good liver microsomal stability, and acceptable pharmacokinetic properties. Pharmacokinetic studies were commissioned by Medicilon.

Jul 06,2023

TRIM24和BRPF1是癌癥的潛在治療靶點。Y08624是一種新型TRIM24/BRPF1雙重抑制劑，具有良好的Caco-2滲透性。Caco-2 滲透性測定通過尊龍凱時進行

TRIM24 (tripartite motif-containing protein 24) and BRPF1 (bromodomain and PHD finger containing protein 1) are epigenetics “readers”and potential therapeutic targets for cancer and other diseases. Y08624 (Compound 20l) is a new TRIM24/BRPF1 dual inhibitor. Y08624 displays reasonable Caco-2 permeability. Caco-2 permeability assay was performed by Medicilon.